Infectious Disease Control APAC News & Press Release Distribution

Infectious Disease Control

All
Global

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...

2023-08-14 21:30 2518

Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]

* First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] — one of the leading causes of death inHong Kong[4] — has been approved by Hong Kong Department of Health inApril 2023 and is now available in Hong ...

2023-08-10 14:15 2964

Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes

LONDON, July 28, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'. On WHD, the World Hepatitis Alliance (WHA) joins together with its global network of 323 members in over 100 countries to lead the campaign internationally to accelerate th...

2023-07-28 04:02 3036

Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress

TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...

2023-07-27 10:57 6308

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...

2023-07-06 07:25 4764

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...

2023-07-06 07:19 5306

New Survey Reveals Insights on Singapore Workers' Preparedness for Digital Transformation

Study sheds light on perceptions, behaviours and changes towards digitalisation in the aftermath of the COVID-19 pandemic SINGAPORE, July 3, 2023 /PRNewswire/ -- Reeracoen, a leading provider of human resource services inSingapore, has released its latest report titled "Employee Attitudes Toward...

2023-07-03 07:45 3177

New Survey Reveals Insights on Singapore Workers' Preparedness for Digital Transformation

Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective

TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...

2023-06-29 00:00 3891

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...

2023-06-26 07:30 4172

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...

2023-06-25 20:00 5300

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...

2023-06-18 03:30 5406

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

* Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign * Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immu...

2023-06-16 06:05 3881

Treating COVID with Metformin Reduces Long COVID Rates

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseasessupported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection. The trial also saw a 42% reduction in emergency room visi...

2023-06-09 21:00 6444

Treating COVID with Metformin Reduces Long COVID Rates

China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use

CHENGDU, China, June 9, 2023 /PRNewswire/ -- On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in ...

2023-06-09 11:59 5274

China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use

CAMH study confirms ongoing brain inflammation associated with long COVID

Researchers using advanced brain imaging are first to find increase in protein marker of inflammation in illness affecting 200 million globally TORONTO, June 2, 2023 /PRNewswire/ -- A new CAMH study published in the journalJAMA Psychiatry found elevated levels of inflammation in the brain of pa...

2023-06-02 04:07 3435

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or...

2023-06-01 08:00 4459

Chula Researchers Discover "Highly Effective Antibodies against COVID-19," Leading to "COVITRAP Nasal Spray" to Curb Infection at the Start

BANGKOK, May 24, 2023 /PRNewswire/ -- A research team at the Center of Excellence in Systems Biology, Faculty of Medicine,Chulalongkorn University, has identified "highly effective antibodies against COVID-19" from the human body. These antibodies have been developed into an innovation called "C...

2023-05-24 10:00 3822

The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

CHENGDU, China, May 18, 2023 /PRNewswire/ -- On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center,Sichuan University against the most recent cir...

2023-05-18 21:23 6386

The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2023-05-18 20:25 4599

Parliamentarians from 23 countries call on G7 leaders to invest in neglected tropical diseases

Uniting to Combat Neglected Tropical Diseases (unitingtocombatntds.org) releases letter signed by 36 Parliamentarians from 23 countries calling on G7 Leaders to invest in NTDs. LONDON, May 17, 2023 /PRNewswire/ -- To: Fumio Kishida, Prime Minister, Japan (Host) Joe Biden, President, United Stat...

2023-05-17 17:40 3836

1 ... 3 4 567 8 9 ... 26